{
    "nctId": "NCT02284581",
    "briefTitle": "Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments",
    "officialTitle": "Evaluation of Medical Treatments (Chemotherapy, Hormonal Therapy and Biological Therapies) in Metastatic Breast Cancer Patients According to Biologic Subtype and Line of Treatment",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 10000,
    "primaryOutcomeMeasure": "Duration and number of lines' treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\nRetrospective cohort All consecutive metastatic breast cancers patients treated in the participating site with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from last contact with patient or death which ever event comes first retrospectively back until 1 st of January 2000\n\nProspective cohort All new consecutive metastatic breast cancers patients will be treated in the participating site with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy)from site activation to June 2023.\n\nFor the ancillary study\n\n* Patients eligible for GIM 14 - BIO-META study\n* HR+ HER2- patients newly diagnosed for mBC receiving CDk4/6 inhibitors as first-line or second-line treatment\n* Written informed consent\n\nExclusion Criteria:\n\nNot consecutive metastatic breast cancer patients grouped for a particular biological type (for example: all HER2 positive patients).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}